Pathogenic cellular and molecular mediators in lupus nephritis

Chandra Mohan, Ting Zhang, Chaim Putterman

Research output: Contribution to journalReview articlepeer-review


Kidney involvement in patients with systemic lupus erythematosus — lupus nephritis (LN) — is one of the most important and common clinical manifestations of this disease and occurs in 40–60% of patients. Current treatment regimens achieve a complete kidney response in only a minority of affected individuals, and 10–15% of patients with LN develop kidney failure, with its attendant morbidity and considerable prognostic implications. Moreover, the medications most often used to treat LN — corticosteroids in combination with immunosuppressive or cytotoxic drugs — are associated with substantial side effects. Advances in proteomics, flow cytometry and RNA sequencing have led to important new insights into immune cells, molecules and mechanistic pathways that are instrumental in the pathogenesis of LN. These insights, together with a renewed focus on the study of human LN kidney tissue, suggest new therapeutic targets that are already being tested in lupus animal models and early-phase clinical trials and, as such, are hoped to eventually lead to meaningful improvements in the care of patients with systemic lupus erythematosus-associated kidney disease.

Original languageEnglish
Pages (from-to)491-508
Number of pages18
JournalNature Reviews Nephrology
Issue number8
Early online date24 May 2023
StatePublished - Aug 2023

All Science Journal Classification (ASJC) codes

  • Nephrology


Dive into the research topics of 'Pathogenic cellular and molecular mediators in lupus nephritis'. Together they form a unique fingerprint.

Cite this